FDA Approves Lipfendra to Reduce Cholesterol in High-Risk Patients

The FDA approved Merck's Lipfendra nationwide for high-risk patients already taking statins. It is the first oral PCSK9 inhibitor. The approval is based on two studies and long-term data is limited to one year. Patients must take the medication on an empty stomach.

CHECKED · 1 SOURCE · UNCORROBORATED ✓